EYPT - CIK 0001314102
EyePoint Pharmaceuticals, Inc. (EYPT) reported net income of -$231.96M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$231.96M | -77.2% |
| FY 2024 | -$130.87M | -84.9% |
| FY 2023 | -$70.80M | +30.8% |
| FY 2022 | -$102.25M | -75.0% |
| FY 2021 | -$58.42M | -28.7% |
| FY 2020 | -$45.39M | +20.1% |
| FY 2019 | -$56.79M | +34.1% |
| FY 2018 | -$86.13M | -365.9% |
| FY 2017 |
EyePoint Pharmaceuticals, Inc. (EYPT) reported net income of -$231.96M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, EyePoint Pharmaceuticals, Inc.'s net income declined from -$8.63M to -$231.96M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$18.48M |
| +14.2% |
| FY 2016 | -$21.55M | -439.5% |
| FY 2015 | $6.35M | +147.5% |
| FY 2014 | -$13.36M | -12.2% |
| FY 2013 | -$11.90M | +52.1% |
| FY 2012 | -$24.84M | -187.8% |
| FY 2011 | -$8.63M | - |